Key facts
- It has raised $132.5M across 10 recorded rounds; the latest was Later Stage VC ($60.0M) in Sep 2024.
- Notable investors include National Institutes of Health, Johnson & Johnson JJDC, Innovation Partnerships, Novartis Venture Fund, University of Michigan Endowment — 26 tracked in total.
- ONL Therapeutics has filed 10 Form Ds with the SEC since 2014, most recently Sep 2024 ($60.0M sold to 35 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 10 rounds
- ·The complete investor list — 26 names
- ·Watchlist + deal alerts for ONL Therapeutics
Funding rounds
10 roundsAbout ONL Therapeutics
Operator of a biopharmaceutical company intended to protect and improve patients' vision with various retinal diseases and conditions. The company develops therapeutics treatments for serious, vision-threatening retinal diseases and conditions with small-molecule peptides for the protection of photoreceptors in retinal detachment, enabling patients to have successful surgeries and improved outcomes.
- Sector
- Healthcare
- HQ
- Ann Arbor, MI, United States
- Founded
- 2011
- Employees
- 29
- Website
- onltherapeutics.com/
- Ownership
- Privately Held (backing)
ONL Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ONL Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ONL Therapeutics in its N-PORT filings yet. We sweep new filings monthly.